Funding Round attributes
Dash Bio, a biotechnology firm based in Newton, Massachusetts, has successfully raised $6.5 million in seed financing to enhance its operations and accelerate the development of innovative solutions in drug development. The funding round was led by Freestyle Capital, with participation from Swift Ventures, LifeX Ventures, and additional private investors.
Founded by Dave Johnson (CEO), Ander Tallett (COO), and Ely Porter, Dash Bio is focused on revolutionizing the drug development lifecycle through a technology-first approach. The company is integrating artificial intelligence (AI), robotics, and automated software systems to streamline the process of bringing new drugs to market. One of its first initiatives is a highly automated clinical bioanalysis lab designed to deliver GLP-compliant services, which are crucial for regulatory approvals in drug development.
